Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cells are more precise and sophisticated in their ability ...
Apr 15, 2022
0
27
Like the hardiest weed, glioblastoma almost always springs backâusually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...
Aug 8, 2022
0
1770
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research. In two new papers, scientists at UC San Francisco and Princeton University present complementary strategies ...
Nov 26, 2020
0
92
Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the U.S., have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in ...
Mar 13, 2023
0
71
Peter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in fighting solid cancer tumors.
Apr 7, 2023
0
94
A promising new way to treat some types of cancer is to program the patient's own T cells to destroy the cancerous cells. This approach, termed CAR-T cell therapy, is now used to combat some types of leukemia, but so far ...
Jul 11, 2019
0
256
A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy ...
Dec 3, 2020
0
591
UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.
Nov 8, 2023
0
84
Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target ...
Sep 2, 2021
0
59
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
